Get started
Alnylam Pharmaceuticals, IncAlnylam Pharmaceuticals, IncAlnylam Pharmaceuticals, Inc

Alnylam Pharmaceuticals, Inc

No trades
See on Supercharts
OverviewFinancialsNewsIdeasDiscussionsTechnicalsForecastSeasonalsBondsETFs

0HD2 chart


Full chart

0HD2 upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪59.56 B‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−2 USD
Net income (FY)
‪−278.16 M‬ USD
Revenue (FY)
‪2.25 B‬ USD
Shares float
‪125.52 M‬
Beta (1Y)
1.13

Employees


Employees (FY)
‪2.23 K‬
Change (1Y)
+130 +6.19%
Revenue / Employee (1Y)
‪1.01 M‬ USD
Net income / Employee (1Y)
‪−124.73 K‬ USD

About Alnylam Pharmaceuticals, Inc.


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Yvonne L. Greenstreet
Website
alnylam.com
Headquarters
Cambridge
Founded
2002
ISIN
US02043Q1076
FIGI
BBG00JVRN4W5
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. Schimmel, and Phillip Allen Sharp on June 14, 2002 and is headquartered in Cambridge, MA.

Check out other big names from the same industry as 0HD2.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

0HD2 news



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

0HD2 highest yielding bonds


ALNY5653584
Alnylam Pharmaceuticals, Inc. 1.0% 15-SEP-2027
Yield to maturity
—
Maturity date
Sep 15, 2027
US2043QAC1
Alnylam Pharmaceuticals, Inc. 0.0% 15-SEP-2028
Yield to maturity
—
Maturity date
Sep 15, 2028

See all 0HD2 bonds 

Sparks


Curated watchlists where 0HD2 is featured.

See all sparks 

Frequently Asked Questions


The current price of 0HD2 is 461 USD — it has increased by 1.97% in the past 24 hours. Watch Alnylam Pharmaceuticals, Inc stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on LSE exchange Alnylam Pharmaceuticals, Inc stocks are traded under the ticker 0HD2.
0HD2 stock has risen by 0.88% compared to the previous week, the month change is a −1.66% fall, over the last year Alnylam Pharmaceuticals, Inc has showed a 70.89% increase.
We've gathered analysts' opinions on Alnylam Pharmaceuticals, Inc future price: according to them, 0HD2 price has a max estimate of 570.00 USD and a min estimate of 325.00 USD. Watch 0HD2 chart and read a more detailed Alnylam Pharmaceuticals, Inc stock forecast: see what analysts think of Alnylam Pharmaceuticals, Inc and suggest that you do with its stocks.
0HD2 reached its all-time high on Sep 10, 2025 with the price of 485 USD, and its all-time low was 65 USD and was reached on Nov 15, 2018. View more price dynamics on 0HD2 chart.
See other stocks reaching their highest and lowest prices.
0HD2 stock is 2.53% volatile and has beta coefficient of 1.13. Track Alnylam Pharmaceuticals, Inc stock price on the chart and check out the list of the most volatile stocks — is Alnylam Pharmaceuticals, Inc there?
Today Alnylam Pharmaceuticals, Inc has the market capitalization of ‪60.08 B‬, it has decreased by −3.60% over the last week.
Yes, you can track Alnylam Pharmaceuticals, Inc financials in yearly and quarterly reports right on TradingView.
Alnylam Pharmaceuticals, Inc is going to release the next earnings report on Oct 23, 2025. Keep track of upcoming events with our Earnings Calendar.
0HD2 earnings for the last quarter are −0.51 USD per share, whereas the estimation was −0.54 USD resulting in a 6.20% surprise. The estimated earnings for the next quarter are 0.37 USD per share. See more details about Alnylam Pharmaceuticals, Inc earnings.
Alnylam Pharmaceuticals, Inc revenue for the last quarter amounts to ‪773.69 M‬ USD, despite the estimated figure of ‪662.87 M‬ USD. In the next quarter, revenue is expected to reach ‪921.30 M‬ USD.
0HD2 net income for the last quarter is ‪−66.28 M‬ USD, while the quarter before that showed ‪−57.48 M‬ USD of net income which accounts for −15.31% change. Track more Alnylam Pharmaceuticals, Inc financial stats to get the full picture.
No, 0HD2 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Sep 25, 2025, the company has ‪2.23 K‬ employees. See our rating of the largest employees — is Alnylam Pharmaceuticals, Inc on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Alnylam Pharmaceuticals, Inc EBITDA is ‪−123.69 M‬ USD, and current EBITDA margin is −5.35%. See more stats in Alnylam Pharmaceuticals, Inc financial statements.
Like other stocks, 0HD2 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Alnylam Pharmaceuticals, Inc stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Alnylam Pharmaceuticals, Inc technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Alnylam Pharmaceuticals, Inc stock shows the buy signal. See more of Alnylam Pharmaceuticals, Inc technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.